A new wave of hope is washing over the oncology field with Myricx Bio’s impressive £90 million ($114 million) Series A funding. This UK biotech company, unlike its peers, isn’t taking an incremental step forward. Instead, they’re wielding a whole new weapon in the fight against cancer: N-Myristoyltransferase inhibitor (NMTi) antibody-drug conjugates (ADCs). The significance…
Beacon Therapeutics, a pioneering ophthalmic gene therapy company dedicated to combating blinding retinal diseases, has secured $170 million in Series B funding, marking a significant stride towards advancing its transformative treatments. Led by Forbion and supported by existing investors Syncona and Oxford Science Enterprises, alongside newcomers TCGX and Advent Life Sciences, this funding round will…
Rejuvenate Bio, a pioneering biotechnology firm specializing in gene therapies, announced today the reception of a $4 million grant from the California Institute for Regenerative Medicine (CIRM) to propel the development of its innovative gene therapy, RJB-0402, aimed at treating desmoplakin gene variant arrhythmogenic cardiomyopathy (DSP ACM). Desmoplakin gene variant arrhythmogenic cardiomyopathy (DSP ACM) is…
Anbogen Therapeutics, a leading name in cancer therapeutics development, has announced the successful completion of an oversubscribed A+ round financing, securing USD 7.3 million to advance their groundbreaking cancer treatment, ABT-301. This latest funding round follows on the heels of a USD 12.5 million Series A round earlier this year, bringing Anbogen’s total funding to…
Kanvas Biosciences, a pioneering spatial biology company, has announced a significant stride in its mission to revolutionize healthcare with microbiome-based therapies. With an additional $12.5 million in funding co-led by DCVC and Lions Capital LLC, and supported by FemHealth Ventures, Germin8, Ki Tua Fund, and Pangaea Ventures, alongside existing investors, the company’s total funding now…
Waypoint Bio, a pioneering biotechnology firm, has secured $14.5 million in seed funding led by Hummingbird Ventures, alongside Recode Ventures and Fifty Years, to advance its cutting-edge approach in developing cell therapies for solid tumors. Founded by MIT alumni Xinchen Wang and David Phizicky, Waypoint Bio harnesses in vivo spatial pooled screening technology to drive…
RareCyte, Inc., a pioneering Life Sciences company renowned for its Precision Biology platforms, has announced the successful completion of a $20 million financing round aimed at bolstering its Orion™ Spatial Biology platform. This funding, sourced from a blend of new and existing investors, including Forest Road, Arboretum Ventures, and F-Prime Capital, underscores RareCyte’s commitment to…
Vertus Energy, a pioneering industrial biotech firm specializing in Waste-to-X solutions, has successfully raised €8.75 million in a Seed funding round to advance its innovative approach to managing bacteria behavior in biogas production. This funding marks a significant milestone for Vertus Energy as it strives to redefine waste treatment by converting it into valuable resources…
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a pioneering biopharmaceutical firm renowned for its innovative approach to severe ischemic diseases, has announced a significant milestone today. The company successfully finalized agreements for a private placement offering, securing $11.8 million in gross proceeds from accredited investors. This strategic funding round underscores DiaMedica’s commitment to advancing clinical and product…
Augustine Therapeutics, a pioneering biotechnology firm specializing in innovative therapies for neurodegenerative and cardiometabolic diseases, announced a significant milestone today with the successful completion of a EUR 17 million (USD 18.5 million) first closing of its Series A funding round. This financing, led by Asabys Partners and supported by Eli Lilly and Company and the…
